Epigenomics GMBH
This article was originally published in Start Up
Executive Summary
Epigenomics is developing diagnostics based on individuals' genetic profiles. Its core technology is based on measurements of DNA methylation: the company believes methyl groups, which stick up like flags from stretches of DNA, may indicate the absence or presence of disease.
You may also be interested in...
Epigenomics Gets What Companies Rarely Do: A Huge Deal
Roche Diagnostics and Epigenomics AG, a start-up diagnostics company, have signed a three-year collaboration to find new cancer diagnostic markers, a deal that could bring Epigenomics as much as $100 million--if all of the markers covered get to market. Epigenomics is working on DNA methylation based biomarkers for cancer and will identify the markers; Roche will develop them into tests and market them worldwide.
Epigenomics Gets What Companies Rarely Do: A Huge Deal
Roche Diagnostics and Epigenomics AG, a start-up diagnostics company, have signed a three-year collaboration to find new cancer diagnostic markers, a deal that could bring Epigenomics as much as $100 million--if all of the markers covered get to market. Epigenomics is working on DNA methylation based biomarkers for cancer and will identify the markers; Roche will develop them into tests and market them worldwide.
Overcoming Skepticism About Cancer Diagnostics
In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.